Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

NCT01068782 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT01068782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01068782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Lead sponsor
Exelixis
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2010
Completion date
October 31, 2013
Enrollment
19 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytic tumors